Iktos Announces Research Collaboration with Janssen to Utilize Iktos’ Artificial Intelligence Technology to Increase Speed & Efficiency of Small Molecule Drug Discovery

    Reading Time: 2 minutes

    PARIS–(BUSINESS WIRE)–Iktos, a company specializing in Artificial Intelligence (AI)
    technologies applied to new drug design, announced today the initiation
    of a collaboration agreement with Janssen Pharmaceutica NV. As part of
    the collaboration, Iktos virtual drug design technology will be
    implemented and applied to several Janssen small molecule drug discovery
    projects. Iktos will collaborate with Janssen to develop new
    applications, leveraging Iktos’ proprietary know-how in deep generative
    models applied to chemistry and Janssen expertise in AI-enabled
    prediction of small molecule activities.

    Building on deep generative models, Iktos is developing a proprietary
    and innovative technology for in silico drug design which has the
    potential to enable vast improvements in drug discovery workflows, based
    on its unique capacity to explore chemical space with speed and
    efficiency, thus enabling identification of molecules that meet the
    desired criteria in a given research project.

    “We are thrilled to be able to announce a strategic collaboration with
    Janssen, one of the largest pharma companies in the world, and highly
    respected for the quality of their science and their visionary
    perspective regarding the use of big data and machine learning to
    progress pharma R&D efficiency,” commented Yann Gaston-Mathé, CEO of
    Iktos. “It is a major recognition for Iktos to be selected by Janssen as
    a partner for implementation and development of generative modeling
    technology for new drug design. Iktos has been a pioneer in the
    application of generative models for drug discovery and is emerging as a
    world leader in a technology that has the potential to disrupt the way
    new therapeutics are designed.”

    Iktos has recently announced collaborations with several
    biopharmaceutical companies where Iktos AI technology is used to
    accelerate the design of promising compounds, and has published, at the
    EFMC 2018 meeting, an experimental validation of the technology in a
    real-life drug discovery project. Iktos is planning to release its SaaS
    software, Makya™, as a beta version available for testing by customers,
    by mid-2019.

    About Iktos

    Incorporated in October 2016, Iktos is a French start-up company
    specializing in the development of artificial intelligence solutions
    applied to chemical research, more specifically medicinal chemistry and
    new drug design. Iktos is developing a proprietary and innovative
    solution based on deep learning generative models, which enables the use
    of existing data to design molecules that are optimized in silico
    to meet the success criteria of a small molecule discovery project. The
    use of Iktos technology enables major productivity gains in upstream
    pharmaceutical R&D. Iktos offers its technology to its customers both as
    professional services and as a SaaS software platform, Makya™.
    information on: www.iktos.ai


    Yann Gaston-Mathé (CEO)
    [email protected]
    6 30 07 99 26